Composition: Anacare Tablet: Each film coated tablet contains Anastrozole USP 1 mg.
Indications: Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. Anastrozole is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole.
Dosage & Administration: The dose of Anacare is one tablet 1 mg taken once a day. For patients with advanced breast cancer, Anastrozole should be continued until tumor progression. For adjuvant treatment of early breast cancer in postmenonausal women, the optimal duration of therapy is unknown. Patients with Hepatic Impairment: No changes in dose are recommended for patients with mild- to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. Patients with Renal Impairment: No changes in dose are necessary for patients with renal impairment.
Pregnancy: Pregnancy Category X. Nursing Mothers: It is not known it Anastrozole is excreted in human milk. Because many drugs are excreted in human milk or the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: The safety and efficacy of Anastrozole in pediatric patients have not been established. Geriatric Use: The pharmacokinetics of Anastrozole are not affected by age.
Packing: Anacare Tablet: Each box contains 28 tablets in Alu-Alu blister pack.